102 related articles for article (PubMed ID: 17137218)
1. Valsartan improves the lower limit of cerebral autoregulation in rats.
Takada J; Ibayashi S; Ooboshi H; Ago T; Ishikawa E; Kamouchi M; Kitazono T; Iida M
Hypertens Res; 2006 Aug; 29(8):621-6. PubMed ID: 17137218
[TBL] [Abstract][Full Text] [Related]
2. No effect of angiotensin II AT(2)-receptor antagonist PD 123319 on cerebral blood flow autoregulation.
Estrup TM; Paulson OB; Strandgaard S
J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):188-92. PubMed ID: 11881121
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II AT2 receptor stimulation extends the upper limit of cerebral blood flow autoregulation: agonist effects of CGP 42112 and PD 123319.
Näveri L; Strömberg C; Saavedra JM
J Cereb Blood Flow Metab; 1994 Jan; 14(1):38-44. PubMed ID: 8263056
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
5. Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats.
Wang T; Yin KS; Liu KY; Lu GJ; Li YH; Chen JD
Chin Med J (Engl); 2008 Nov; 121(22):2312-9. PubMed ID: 19080339
[TBL] [Abstract][Full Text] [Related]
6. The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism.
Mitchell A; Rushentsova U; Siffert W; Philipp T; Wenzel RR
Clin Pharmacol Ther; 2006 Mar; 79(3):274-81. PubMed ID: 16513451
[TBL] [Abstract][Full Text] [Related]
7. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
Tominaga N; Robert A; Izuhara Y; Ohtomo S; Dan T; Chihara K; Kurokawa K; Van Ypersele de Strihou C; Miyata T
Nephrology (Carlton); 2009 Sep; 14(6):581-7. PubMed ID: 19712258
[TBL] [Abstract][Full Text] [Related]
8. Effects of benidipine, a long-lasting dihydropyridine-Ca2+ channel blocker, on cerebral blood flow autoregulation in spontaneously hypertensive rats.
Ikeda J; Yao K; Matsubara M
Biol Pharm Bull; 2006 Nov; 29(11):2222-5. PubMed ID: 17077518
[TBL] [Abstract][Full Text] [Related]
9. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
Chan P; Liu IM; Tzeng TF; Yang TL; Cheng JT
Diabetes Obes Metab; 2007 Jan; 9(1):39-49. PubMed ID: 17199717
[TBL] [Abstract][Full Text] [Related]
10. Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.
Ledingham JM; Laverty R
Clin Exp Pharmacol Physiol; 2005 Nov; 32(11):919-25. PubMed ID: 16405447
[TBL] [Abstract][Full Text] [Related]
11. Treatment with valsartan stimulates endothelial progenitor cells and renal label-retaining cells in hypertensive rats.
Yoshida Y; Fukuda N; Maeshima A; Yamamoto C; Matsumoto T; Ueno T; Nojima Y; Matsumoto K; Soma M
J Hypertens; 2011 Jan; 29(1):91-101. PubMed ID: 20935578
[TBL] [Abstract][Full Text] [Related]
12. Sodium, arterial stiffness, and cardiovascular mortality in hypertensive rats.
Mercier N; Labat C; Louis H; Cattan V; Benetos A; Safar ME; Lacolley P
Am J Hypertens; 2007 Mar; 20(3):319-25. PubMed ID: 17324746
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
Yamamoto E; Kataoka K; Shintaku H; Yamashita T; Tokutomi Y; Dong YF; Matsuba S; Ichijo H; Ogawa H; Kim-Mitsuyama S
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2569-75. PubMed ID: 17932313
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure.
Kumai Y; Ooboshi H; Ago T; Ishikawa E; Takada J; Kamouchi M; Kitazono T; Ibayashi S; Iida M
Exp Neurol; 2008 Apr; 210(2):441-8. PubMed ID: 18177860
[TBL] [Abstract][Full Text] [Related]
15. Endothelial progenitor cell differentiation and senescence in an angiotensin II-infusion rat model.
Kobayashi K; Imanishi T; Akasaka T
Hypertens Res; 2006 Jun; 29(6):449-55. PubMed ID: 16940708
[TBL] [Abstract][Full Text] [Related]
16. Cerebral blood flow (CBF) autoregulation in spontaneously hypertensive rats (SHR) during chronic administration of a theophylline derivative (P-23).
Kozłowska T; Olejnik A; Krawczak J; Chodera A; Barry D; Pedersen E
Pol J Pharmacol Pharm; 1989; 41(6):611-8. PubMed ID: 2518576
[TBL] [Abstract][Full Text] [Related]
17. New basic science initiatives with the angiotensin II receptor blocker valsartan.
de Gasparo M
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S3-5. PubMed ID: 17199210
[TBL] [Abstract][Full Text] [Related]
18. Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Thai H; Guarraia D; Johnson N; Goldman S; Gaballa MA
J Cardiovasc Pharmacol; 2007 Dec; 50(6):703-7. PubMed ID: 18091589
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 (AT1)-receptor blocker prevents impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking in rats.
Iida H; Iida M; Takenaka M; Fujiwara H; Dohi S
Life Sci; 2006 Feb; 78(12):1310-6. PubMed ID: 16213531
[TBL] [Abstract][Full Text] [Related]
20. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats.
Kassab S; Garadah T; Abu-Hijleh M; Golbahar J; Senok S; Wazir J; Gumaa K
J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):206-11. PubMed ID: 17318789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
